

Examination Sets



The sample provides incomplete information,
which must be integrated with

- Biological variability
- Patient's clinical history

*Having anamnestic data helps to
understand abnormal results better*

Causes of biological variability

- Sex
- Ethnic group
- Age
- Body mass
- Circadian rhythms
- Change of season
- Menstrual cycle
- Pregnancy

- Diet
- Food consumption
- Posture
- Stress
- State of hydration
- Physical tiredness
- Altitude

Glycemia



Glycemia is the concentration of glucose in the blood

It is measured using blood from a vein or
capillary

It should be measured after 8 hours of no
food consumption

Normal result: **70-110 mg/dL**

Hypoglycemia

Plasmatic glycemia is under 45 mg/dL

After fasting

Excess of insulin production

Abnormal anti-insulin hormones (Addison's disease, Hypothyroidism)

Medication (anti-diabetics)

Particular situations (pregnancy, malnutrition, hepatic disease)

Hyperglycemia and diabetes clinical classification

- **Diabetes mellitus type 1**

- Immunomediate
- Young onset with acute symptoms
- LADA or Diabetes 1.5 (Latent Autoimmune Diabetes of Adults) over 35 years

- **Diabetes mellitus type 2**

- Is the most common form, representing 90-95% of all forms
- Insulin resistance
- Medication induced
- Infection induced
- Pregnancy
- Pancreatic disorders

Criteria for the diagnosis of diabetes mellitus

- Symptoms of diabetes (polyuria, polydipsia, loss of weight) associated to incidental finding of blood sugar ≥ 200 mg/dL
- Fasting glucose (at least 8 hours) ≥ 126 mg/dL
- Post charge of glucose (WHO), glycemia ≥ 200 mg/dL after charge of 75 g of glucose

1) To make a diagnosis of diabetes is necessary to have at least one of three criteria

2) One of three criteria should be confirmed in a subsequent day

Category of patients with abnormal glucose homeostasis

- Fasting glucose ≥ 110 mg/dL=**abnormal**
- Fasting glucose ≥ 126 mg/dL=**diagnosis of diabetes**

Laboratory parameters according to American Diabetes Association

- Pre diabetes

- fasting **glycemia** 100 - 125 mg/dl

- glycemia after **OGTT(oral glucose tolerance test)** 140 - 199 mg/dl.

- level of **haemoglobin glicata** 5.7 – 6.4%

- Diabetes

- fasting **glycemia** over 126 mg/dl

- glycemia after **OGTT** over 200 mg/dl

- level of **haemoglobin glicata** over 6.5%

Diabetes and laboratory analysis

- Glycemia***
- Glycosuria(unreliable)
- Glycosylated Haemoglobin
(HbA1c) ***
- Microalbuminuria***
 - Ketons***

Other criteria of ADA

- Screening for the diagnosis of diabetes and pre-diabetes should be accomplished in all adult subjects, even if they have no symptoms
 - Families of first-degree diabetics
- Women who have given birth to macrosomic fetuses or who have been diagnosed in the past with gestational diabetes
- Arterial hypertension with values equal to or greater than 140/90 mmHg or in hypertensive treatment
- Hdl cholesterol values below 35 mg / dl or triglycerides greater than 250 mg / dL
- Early detection of high glycemic values even though sporadic
- A history of cardiovascular disease
- Women With polycystic ovary syndrome

Lipidic profile



Risk factors

Major cardiovascular risk factors *

- Cigarette smoke
- Hypertension
- High plasma cholesterol levels and LDL cholesterol
- Reduction of plasma HDL cholesterol levels
- Diabetes mellitus
- Old age

Other Risk Factors

- Obesity (abdominal)
- Physical inactivity
- Family history
- Ethnicity
- Psychosociological factors
- High triglycerides
- Fibrinogen and high PCR
- High Omocysteine
- Lipoprotein (a)

*Framingham Heart Study, American Heart Association, American College of Cardiology

Adult Treatment Panel III*

Suggests determination of a complete lipid profile at fasting for at least 12 hours including:

Total cholesterol

LDL-cholesterol

HDL-cholesterol

Triglycerides

At least once every 5 years in all adults over the age of 20

* Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults

Table II.2–4. ATP III Classification of Total Cholesterol and LDL Cholesterol

Total Cholesterol (mg/dL)		LDL Cholesterol (mg/dL)	
<200	Desirable	<100	Optimal
		100–129	Near optimal/ above optimal
200–239	Borderline High	130–159	Borderline High
≥240	High	160–189	High
		≥190	Very High

Table II.3–2. ATP III Classification of HDL Cholesterol**Serum HDL Cholesterol (mg/dL)**

<40 mg/dL	Low HDL cholesterol
≥60 mg/dL	High HDL cholesterol

Table II.3–1. Classification of Serum Triglycerides

Triglyceride Category	ATP II Levels	ATP III Levels
Normal triglycerides	<200 mg/dL	<150 mg/dL
Borderline-high triglycerides	200–399 mg/dL	150–199 mg/dL
High triglycerides	400–1000 mg/dL	200–499 mg/dL
Very high triglycerides	>1000 mg/dL	≥500 mg/dL

Parameters	Reference values
Total cholesterol	<200 mg/dl (desirable) 200-239 md/dl (borderline) >240 mg/dl (high)
HDL	>35 mg/dl
LDL	<130 mg/dl*
VLDL	≤30 mg/dl
Triglycerides	<150 mg/dl

*** <100 mg / dl in patients with high cardiovascular risk,
<70 mg / dl in patients with very high cardiovascular risk.**

Parameters	Reference values
Lipoprotein(a)	<30 mg/dL
Homocysteine	16-30µmol/L* 31-100µmol/L** >100µmol/L***
Fibrinogen	150-400 mg/dL
Protein C reactive (hsPCR)	<1 mg/L* 1-3 mg/L** >3 mg/L***

Parameters

Reference values

Lipoprotein(a)

<30 mg/dL

Homocysteine

16-30µmol/L*
31-100µmol/L**
>100µmol/L***

Fibrinogen

150-400 mg/dL


Protein C reactive
(hsPCR)

<1 mg/L*
1-3 mg/L**
>3 mg/L***

Hepatic profile



Liver function



Intoxication of the Liver

Induced by

Virus Infection

A, B, C, Delta Hepatitis
(acute & chronic states)

Toxic Metabolic Disorders

Hyperalimentation
(fat, carbohydrate, proteins & vitamins)

Diabetes Mellitus

Dyslipoproteinemias

Hyperthyroidism

Malnutrition

(Kwashiorkor, protein deficiency, metatroph)

Chemical Noxae

Longterm Industrial Contact

Accidental Intake

Poisoning by Inhalation

Alcohol

Chronic Alcohol Abuse

Acute Intoxification

Drugs

Chronic Intake

Acute Intoxification

**Decreased
Enzyme
Activity**

**Insufficient
Hepatic
Metabolism**

**Reduced
Detoxification**

Cell Necrosis/Fatty Degeneration/Fibrogenesis

Functional tests

Cytolysis tests

- **AST or GOT: 0-37 U / l** (oxalacetic glutamic transaminase)
- **ALT or GPT: 0-41 U / l** (pyruvic glutamate transaminase)
- **LDH: 0-480 U / l**
- **LDH-1: heart, red blood cells, kidneys, germ cells**
- **LDH-2: heart, red blood cells, kidneys (less than LDH-1)**
- **LDH-3: lungs and other tissues**
- **LDH-4: white blood cells, lymph nodes, muscles, liver**
- **LDH-5: liver, skeletal muscle**

Excretion tests

Alkaline phosphatase: 30-130 U / L

- **Hepatitis**
- **Chronic cholestasis**
- **Tumors**

Gamma-glutamyltransferase (GGT): 0-50 U / l

- **Pancreatic Diseases**
- **Hepatobiliary diseases**
- **Hepatic tumors**
- **Hepatic impairment**
- **Alcohol**
- **Myocardial infarction**

Total bilirubin 0.3 and 1.0 mg / dL
It is the catabolic product of EME

**Indirect or Non-conjugated
Form (Glycuronic Acid)**

**It is normally found in
plasma and increases in
hemolytic diseases**

-Fasting

-S. Gilbert

-Increased emolysis

**Direct or conjugated form
(Glycuronic acid)**

**It is normally found in bile
and increases in obstructive
pathologies**

-Colostatic epathopathy

-Pancreas Tumors

-Calculous bile duct

Renal analysis



- **Azotemia (VN: 10-50 mg / dL):** measure the final product of protein metabolism. Excreted by the urinary tract. It is an index of renal function
- **Causes of hyperazotemia:** pre-renal, renal and post renal disease
- **Creatinine (VN: 0.9-1.3 mg / dL):** creatinine clearance corresponds to the volume of kidney filtration in the time unit. Renal Function Indicator. Increased creatinine always involves a defect of renal function
- **Causes of creatinine increase:** renal parenchyma, vascular, obstructive, degenerative and loss of functioning nephropathies

Emergency

- Blood Gases, Ionized Calcium, Whole Blood glucose, Whole Blood Na, K, Whole Blood Hemoglobin, Prothrombin Time, PT (INR)
- Hematology, coagulation, chemistry tests
- All urine chemistries, lithium, kidney function



Pre operation and Post Operation Set

Basic


- Hb, HCT, WBC, RBC, PLT, blood group, PTT, thrombin time, fibrinogen, HBsAg, glucose, proteins, creatinine, bilirubin, cholesterol, Na, K, Cl, Ca
- Urine: protein, blood, glucose, nitrites, urobilinogen
- Endoscopy: coagulation factors

Enhanced

- ALT, amylase, creatine kinase, C-reactive protein, cholinesterase, urea, ionized calcium, albumin, pH, pCO₂, pO₂, HCO₃sat
- Urine: creatinine, urea, Na, K, sediment
- Diabetic patient: glycemic profile

Inflammatory process activity determination set

The Cardinal Signs of Inflammation



Basic

- Erythrocyte sedimentation rate(ESR-VES), mucoproteins, fibrinogen, C-reactive protein

Enhanced

- Alpha-2-macroglobulin, alpha1 antitrypsin, haptoglobin, ceruloplasmin, C3 C4 complements, Immunoglobulins

Liver set

Basic

- Blood: ALT AST, GMT(GGT) gamma-glutamyltransferase, alkaline phosphatase, bilirubin, prothrombin
- Urine: urobilin, bilirubin

Enhanced

- IgA, IgM, IgG, protein profile, LD, GMT(GGT) gamma-glutamyltransferase, HBsAg, anti-HBc, anti-HAV




Diabetic Set

Basic

- Glucose fasting and 1-2 hrs after meal
- Urine: glucose, ketobody

Enhanced

- Glycemic profile, LDL-C, cholesterol, glycated hemoglobin, HDL




Thyroid set

Basic

- TSH(thyroid-stimulating hormone), fT4

Enhanced

- FT3, T3, T4, cortisol, antithyroglobulin AB, anti-TPO, anti-TSH receptor




Renal set

Basic

- Creatinine, urea
- Urine: pH, protein, blood, leukocytes, nitrites, sediment, quantitative proteinuria

Enhanced

- Na, K, Cl, protein fraction, cholesterol, uric acid, Ca
- Urine: Na, K, Cl, Ca, creatinine, urea, creatinine clearance, protein fraction, C3 complement, C4 complement



Gastroenterologic set

Basic

- Stool: occult bleeding

Enhanced

- Blood: Helicobacter pylori, C-peptide
- Gastric juice
- Duodenal fluid
- Stool



Hematologic Set

Basic

- Erythrocyte sedimentation rate
- Hemoglobin
- Hematocrit
- RBC
- PLT
- WBC
- Blood group
- Coagulation tests
- Fe(iron)
- Tranferrin

Enhanced

- AST and ALT
- Bilirubin
- Creatinine and urea
- LDH
- Ferritin
- HIV test




РОСТ

Reading and understanding blood tests from

Point of care testing
Near-patient testing







VS.



Point-of-care testing definition



The College of American Pathologists (CAP) defines point-of-care testing (POCT) as **testing that does not require dedicated, permanent equipment space**. That is, tests are performed with devices brought to the bedside or other patient locations such as the operating room (OR).

The Clinical Laboratory Improvement Amendment (CLIA) mirrors the CAP definition but further limits the tests and devices to **those where the results are used for clinical decision-making**.

(Dondelinger, R. – 2009)

POCT is also defined as **“any test taken by or on behalf of the treating doctor on-site at the time of consultation, which allows the test result to be used to make immediate decisions about patient treatment”**


(Laurence, C. et al. 2010)

POCT



- Also named Near Patient Testing is used in wards or in pharmacies and is totally automatized. It can be performed by non-medical laboratory staff
- the “farmacia dei servizi e le autoanalisi di prima istanza”, according to the health ministry’s new definition

Decreto 16 dicembre 2010 GU n. 57



[POCT]

Point-of-care testing inside hospitals and clinics.

Outpatient Examining Rooms

Patient Rooms

Operating Rooms

Ambulances

[Previous method]

Bring patients to dedicated test locations (equipped with large machines)

Testing centralized in large hospitals (dedicated test rooms)

Specialized large-scale test centers

[POCT]

Point-of-care testing in locations lacking large-scale equipment. (Eliminates the need for outsourcing.)

Test Facilities

Clinics

[POCT]

New testing modes available. Example: patients can test themselves.

Home

Schools, Workplaces

Pharmacies

Sports Facilities

Total POCT-Percent of revenue by segments

- **Infectious disease 21.9%**
- **Cardiac biomarkers 17.6%**
- **Blood gas/electrolytes 13.4%**
 - **Glucose 13.4%**
 - **Coagulation 13.7%**
 - **Cholesterol 4.2%**
 - **HbA1C 2.6%**
 - **Drugs of abuse 2.5%**
 - **Hematology 2.3%**
 - **Urinalysis 2.3%**
 - **Coagulation 2.2%**
 - **Pregnancy 2.0%**



- **Glycemia**
- **Total proteins (blood)**
- **Triglycerides**
- **Total cholesterol**
- **Cholesterol HDL**
- **Cholesterol LDL**
- **Total bilirubin**
- **Transaminase ALT AST**
- **Gamma-glutamyltransferase (γ GT)**
- **Alkaline phosphatase**
- **Azotemia**
- **Creatinine**
- **Blood panel**



Electrochemistry

Strip device



Cassette and bench-top device





Point of care testing

Near-patient testing

- **Why**: turn around time-TAT and therapeutic TAT
- **When**: need to create new operative procedure
- **How**: through diagnostic systems which provide:

Quality

Easy procedures

Declared clinical objectives